Delta-sleep-inducing peptide

From Retapedia, the free peptide encyclopedia
Medical disclaimer. This article is for informational purposes only and does not constitute medical advice. Consult a qualified clinician before considering any compound discussed below. See Retapedia : Medical disclaimer.

Delta-sleep-inducing peptide is a performance-enhancing peptide studied for its effects on sleep, injectable, subcutaneous. Delta-sleep-inducing peptide (DSIP) is a neuropeptide tied to animal EEG sleep activity; its human sleep role is weak. Shows preclinical antiepileptic activity.

Delta-sleep-inducing peptide (DSIP) is a neuropeptide that when infused into the mesodiencephalic ventricle of recipient rabbits induces spindle and delta EEG activity and reduced motor activities. As an unapproved research peptide with no regulatory approval for human therapeutic use, it is prohibited by WADA at all times under category S0 (non-approved substances).

Natty status
Delta-sleep-inducing peptide is classified as not natty. It is prohibited by WADA and most natural bodybuilding federations. Use places the athlete in the enhanced category. See § Natty status.

Mechanism of action

A neuropeptide named for inducing delta EEG sleep activity in animals, though its own link to human sleep is weak and poorly characterized. Shows preclinical antiepileptic activity.

Reported effects

Effects reported in the literature and from preclinical models include:

  • DSIP and its analogues are proposed to stabilize brain excitability and to act as potent antiepileptics against metaphit-induced generalized audiogenic convulsions. [1] Preclinical
  • Certain artificial DSIP structural analogues significantly promoted slow-wave sleep in rabbits and rats, while DSIP itself did not. [2] Preclinical
  • A naturally occurring dermorphin-decapeptide structurally similar to DSIP promoted slow-wave sleep in rabbits, while its optical isomer suppressed sleep. [2] Preclinical
  • DSIP-like immunoreactivity is concentrated in neurosecretory hypothalamic nuclei of various vertebrate species, which points to a neuroendocrine role rather than direct sleep regulation. [2] Preclinical
  • Biochemical and physiological in vitro studies show a large spectrum of DSIP biological activity, although the sleep-factor hypothesis remains poorly documented. [2] Preclinical

Evidence grades: FDA approvedApproved (non-US)Phase IIIPhase IIPhase IPreclinicalAnecdotal

Natty status

Delta-sleep-inducing peptide is classified as not natty. It appears on the WADA prohibited list and is banned by major natural bodybuilding federations.[3] Use of this compound places the athlete in the enhanced category rather than the natural category in competitive contexts.

Research

The peptide has been the subject of 3 studies and reference works collected on this site. Additional bibliography is in § External links below.

Other peptides in this catalogue with overlapping mechanisms or status:

References

  1. ^ [Endogenous anticonvulsants: neuropeptide Y and delta sleep inducing peptide]. Review
  2. a b c d Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Review
  3. a b World Anti-Doping Agency. (2026). Prohibited List 2026.

External links

This page was last updated on August 4, 2026, at 00:35 (UTC).

Research last reviewed on August 4, 2026.

Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply.